Author(s):
Sajja Keerthi Vathsalya, A. Gnanavel, N. Hima Bindu, S. Saravana Kumar, B. Naveen Kumar
Email(s):
keerthi.vathsalyasajja@gmail.com
DOI:
10.52711/0974-360X.2026.00317 
Address:
Sajja Keerthi Vathsalya, A. Gnanavel, N. Hima Bindu, S. Saravana Kumar, B. Naveen Kumar
Department of Anatomy, Meenakshi Medical College Hospital and Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Meenakshi Nagar, Tamil Nadu – 631552 Mamata Academy of Medical Sciences, Bachupally.
*Corresponding Author
Published In:
Volume - 19,
Issue - 5,
Year - 2026
ABSTRACT:
Background: Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent liver disorder not linked to alcohol consumption. Often associated with metabolic syndrome, NAFLD can progress to severe conditions like non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Current treatment options are limited, prompting growing interest in alternative therapies such as Ayurveda. Objectives: The present study is aimed to assess the therapeutic potential of selected Ayurvedic formulations in mitigating liver damage and lipid abnormalities in albino rats with experimentally induced NAFLD. The objective was to evaluate liver function and lipid profile using blood parameters as a non-invasive alternative to biopsy. Method: Twenty-five male albino rats were divided into seven groups, including normal control, disease-induced, and five treatment groups. NAFLD was induced using a high-fat, high-sugar diet over 28 days. Treatments were administered orally for 21 days. Liver function tests (ALT, AST, ALP, total bilirubin) and lipid profiles (triglycerides, cholesterol) were measured before, during, and after the intervention. Statistical analysis was conducted using ANOVA, with p<0.05 considered significant. Results: The disease-induced group showed significantly elevated liver enzymes and lipid levels, confirming NAFLD. Among treatments, the combination of Arogyavardhini Vati (AV), Triphala Guggulu (TG), Patokaturohinyadi Kashayam (PK), Triphala Churna (TC), and Kutaki Churna (KC) showed the most substantial improvements across all parameters, closely followed by the pioglitazone and Vitamin E group. Groups receiving partial Ayurvedic treatments also showed moderate improvement, while castor oil alone was less effective. Discussion: The findings support the hepatoprotective and lipid-modulatory potential of Ayurvedic combinations in NAFLD management. The multi-component herbal formula demonstrated synergistic efficacy, suggesting that integrated herbal therapy could offer a promising non-invasive approach for NAFLD. Standard treatment with pioglitazone and Vitamin E also proved beneficial, validating its use as a comparator.
Cite this article:
Sajja Keerthi Vathsalya, A. Gnanavel, N. Hima Bindu, S. Saravana Kumar, B. Naveen Kumar. Evaluation of Hypolipidemic Activity of Ayurvedic Formulations on Blood Markers in Albino Rats with Experimental NAFLD. Research Journal Pharmacy and Technology. 2026;19(5):2201-6. doi: 10.52711/0974-360X.2026.00317
Cite(Electronic):
Sajja Keerthi Vathsalya, A. Gnanavel, N. Hima Bindu, S. Saravana Kumar, B. Naveen Kumar. Evaluation of Hypolipidemic Activity of Ayurvedic Formulations on Blood Markers in Albino Rats with Experimental NAFLD. Research Journal Pharmacy and Technology. 2026;19(5):2201-6. doi: 10.52711/0974-360X.2026.00317 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-5-38
6. REFERENCES:
1. Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: Definition and subtypes. Clin Mol Hepatol. 2023 Feb; 29(Suppl): S5–16. doi:10.3350/cmh.2022.0424. PMID: 36577427; PMCID: PMC10029964.
2. Nikunja Kishor Mishra, Amiyakanta Mishra, Rosy Priyadarshini. Non-Alcoholic Fatty Liver Disease (NAFLD) and its Recent Therapeutic Strategies. Research Journal of Pharmacology and Pharmacodynamic. 2023; 15(3): 119-6.
3. Ajmer Singh Grewal, Komal Thapa, Anil Bansal, Deepshikha, Neelam Sharma, Sukhbir Singh. Therapeutic role of nuclear factor erythroid-2 related factor 2 (Nrf2) in liver disorders. Research J. Pharm. and Tech. 2020; 13(8): 3952-3956.
4. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan; 67(1): 328–57. doi: 10.1002/hep.29367. PMID: 28714183.
5. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021 Jun 5; 397(10290): 2212–24. doi: 10.1016/S0140-6736(20)32511-3. PMID: 33894145.
6. Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015 Jan; 62(1 Suppl):S47–64. doi: 10.1016/j.jhep.2014.12.012. PMID: 25920090.
7. Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023 Jul; 119(9): 1787–98. doi:10.1093/cvr/cvad095. PMID: 37338556.
8. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun; 64(6): 1388–402. doi: 10.1016/j.jhep.2015.11.004. PMID: 26516032.
9. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology. 2010 May; 52(5): 1836–46. doi: 10.1002/hep.24001. PMID: 21038418.
10. Manu Mehta, Sarika Gupta, Ajay Duseja. Evaluation of Hepatoprotective effect of Phyllanthus niruri in experimental model of NAFLD. Research Journal of Pharmacy and Technology. 2021; 14(9): 4685-0.
11. Shweta Padher, Vinayak Walhekar, Ravindra Kulkarni, Varsha Pokharkar. Computational based in-silico and molecular docking approach for screening of phyto-constituents on PPAR targets in the treatment of NAFLD. Research Journal of Pharmacy and Technology. 2025; 18(1): 232-8.
12. Ruheena Yasmeen, Humera Hafsa Jabeen, Raafia Aseena, Kaunain Taneem, Umer Syed. An Observational Study to Determine Severity and Complications Associated with Non-Alcoholic Fatty Liver Disease with Special Emphasis on Riskfactors. Research Journal of Pharmacy and Technology 2021; 14(10): 5498-2.
13. Mao J, Tan L, Tian C, Wang W, Zhang H, Zhu Z, et al. Research progress on rodent models and its mechanisms of liver injury. Life Sci. 2024; 337: 122343. doi:10.1016/j.lfs.2023.122343. PMID: 38104671.
14. Reda D, Elshopakey GE, Albukhari TA, Almehmadi SJ, Refaat B, Risha EF, et al. Vitamin D3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the SREBP-1c/PPARα–NF-κB/IRS-2 signaling pathway. Front Pharmacol. 2023 May 16; 14: 1164512. doi:10.3389/fphar.2023.1164512. PMID: 37261280; PMCID: PMC10228732.
15. Pentela Mohana Lakshmi, Jorige Archana. Animal Models of Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease. Asian Journal of Pharmaceutical Research. 2025; 15(1): 51-9.
16. Sahil Choudhari, A. Jothipriya. Non-Alcoholic Fatty Liver Disease . Research J. Pharm. and Tech. 2016; 9(10): 1782-1785.
17. Veena, Vandana Verma, Amrita Ghosh Kar, T. B. Singh, Santosh Kumar Singh. The effect of Pauttika honey and Orlistat on Histological Evaluations of Liver, Kidney and Adipose tissue in high-fat diet-induced Obesity in Charles Foster male rats. Research Journal of Pharmacy and Technology. 2023; 16(6): 2813-8.
18. Fellmann L, Nascimento AR, Tibiriça E, Bousquet P. Murine models for pharmacological studies of the metabolic syndrome. Pharmacol Ther. 2013 Mar; 137(3): 331–40. doi:10.1016/j.pharmthera.2012.11.004. PMID: 23178510.
19. Dasi P, Maheshwar T, Anuradha D, Koteswara Rao CVS. Arogyavardhini Vati – A boon for liver disorders from Ayurveda (Fatty liver). AYUSHDHARA. 2021; 8(4): 3418–22. doi:10.47070/ayushdhara.v8i4.748.
20. Sahoo P, Mahanta NR, Mishra SK. Arogyavardhini Vati – Critical analysis of a miracle drug. Int Res J Ayurveda Yoga. 2024; 7(1): 86–96. doi:10.47223/IRJAY.2024.70115.
21. Khatri B, Methil G, Bhakuni H, Sahu AK. An Ayurvedic approach for non-alcoholic fatty liver associated with Type 2 Diabetes Mellitus: A case report. J Ayurveda Integr Med Sci. 2024 Jun; 9(6): 52. doi:10.21760/jaims.9.6.52.
22. Singh A, Ilango K. Acute and sub-chronic toxicity study of novel polyherbal formulation in non-alcoholic fatty liver using Wistar rats. Future Sci OA. 2024 May 20; 10(1): FSO910. doi:10.2144/fsoa-2023-0118. PMID: 38817372; PMCID: PMC11137787.
23. López-Amador N, Nolasco-Hipolito C, Rojas-Jimeno MJ, Carvajal-Zarrabal O. Liver enzymes in patients diagnosed with non-alcoholic fatty liver
24. disease (NAFLD) in Veracruz: A comparative analysis with the literature. Clin Invest. 2017; 7(1): 25–32. doi:10.4172/clinical-investigation.1000107.
25. Indri Ngesti Rahayu, Asami Rietta Kumala, Dody Taruna, Stefanus Djoni Husodo, Eric Mayo Dagradi, Judya Sukmana. Research Journal of Pharmacy and Technology. 2024; 17(8): 3676-4.
26. Wang Z, Du H, Zhao Y, Ren Y, Ma C, Chen H, Li M, Tian J, Xue C, Long G, Xu M, Jiang Y. Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023 Mar 29; 14: 1111430. doi: 10.3389/fendo.2023.1111430. PMID: 37065735; PMCID: PMC10091905.
27. Kumar G, Srivastava A, Sharma SK, Gupta YK. Safety evaluation of an Ayurvedic medicine, Arogyavardhini Vati on brain, liver and kidney in rats. J Ethnopharmacol. 2012 Mar 6; 140(1): 151–60. doi:10.1016/j.jep.2012.01.004. PMID: 22265751.